Bioness StimRouter™ Neuromodulation System Clinical Data Presented At The 2017 North American Neuromodulation Society’s Annual Meeting

Bioness StimRouter™ Neuromodulation System Clinical Data Presented At The 2017 North American Neuromodulation Society’s Annual Meeting

Share this story with your network

VALENCIA, Calif., Jan. 20, 2017 /PRNewswire/ — Bioness, Inc., the leading provider of state-of-the-art, clinically supported rehabilitation and pain management medical devices, is pleased to announce data surrounding the clinical benefits of its StimRouter Neuromodulation System. At the 2017 North American Neuromodulation Society’s (NANS) Annual Meeting in Las Vegas, Nevada, Dr. Porter McRoberts, a trained Physiatrist and Interventional Spine and Pain Management Specialist in Fort Lauderdale, Florida, shared data indicating that the StimRouter is a promising treatment for post-stroke shoulder pain (PSSP) patients when compared to the alternative options for pain management.

“Post-stroke shoulder pain is a condition that occurs in approximately 30 to 70 percent of stroke patients. This condition contributes to a loss of upper limb use and results in an inability to perform basic daily tasks such as getting dressed or tooth brushing,” said Dr. McRoberts. “While treatments such as oral medication and injections can have a short term impact on managing pain, neuromodulation devices, such as the StimRouter, are designed to target pain at the point of origin and provide relief in a minimally invasive manner with long term effect.”

In a poster presentation, Dr. McRoberts shared data from seven patients that were implanted with the StimRouter in an effort to manage their post-stroke shoulder pain. Using the Visual Analogue Scale (VAS) patients measured pain both before the procedure and up to four months after implant. The patients received care across four different U.S. hospitals in New York, Florida, and Pennsylvania.

Dr. McRoberts and his colleagues found that:

  • PSSP patients implanted with the StimRouter Peripheral Nerve Stimulator experienced an average of 70% reduction in their chronic pain using the Visual Analog Scale (VAS).
  • Peripheral Nerve Stimulation is a promising treatment for PSSP, especially in light of the alternatives for pain management.

The results also show that peripheral nerve stimulation targeting the axillary nerve is a promising treatment for post-stroke shoulder pain patients. Implantable peripheral neurostimulation therapies, like the StimRouter, can be safe and effective pain management techniques as an adjunct to other therapies like Physical/Occupational therapy to help with improving mobility and quality of life.

“The StimRouter has already shown promising results in treating chronic peripheral nerve pain and we are honored to now be sharing its potential for relieving the pain many post-stroke shoulder patients encounter,” said Todd Cushman, President and CEO at Bioness. “Our goal at Bioness is to help patients return to their pre-stroke lives by reducing pain and getting them back into rehabilitation therapy by a Physical/Occupational Therapist. This data is another step forward showing that it is possible for post-stroke patients to regain control of their lives.”

The StimRouter was the first FDA cleared, long-term, minimally invasive peripheral nerve stimulator indicated to treat chronic pain of a peripheral nerve origin. This non-drug, patient-controlled medical device is an adjunct to other modes of therapy and is being well received by patients and clinicians alike.

For more information on the StimRouter or to speak with a patient currently using the device, stop by Bioness’ booth #221 at NANS or visit www.stimrouter.com for videos of real patients sharing their StimRouter experience.

About StimRouter™ Neuromodulation System
The StimRouter™ Neuromodulation System is intended to provide electrical stimulation via a small implanted lead to a target peripheral nerve, for the management of severe intractable chronic pain of peripheral nerve origin in adults, as an adjunct to other modes of therapy. StimRouter is a minimally invasive procedure consisting of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, handheld wireless patient programmer. StimRouter is programmed at the direction of the physician to meet unique pain management requirements.

About Bioness, Inc. Bioness is the leading provider of innovative technologies helping people control pain, regain mobility and improve independence. Bioness solutions include external and implantable functional electrical stimulation (FES) systems, robotic systems and software-based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com.

Media Relations Contact Information
Next Step Communications
bioness@nextstepcomms.com
781.326.1741

StimRouter™ and Bioness® are trademarks of Bioness, Inc. | www.bioness.com | Rx Only
Additional information about StimRouter can be found at www.stimrouter.com.

SOURCE Bioness, Inc.

 

Leave a Comment

Your email address will not be published. Required fields are marked *

*